Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Kristin BairdEdward W Cowen

Abstract

Sclerotic skin manifestations of chronic graft-versus-host disease (ScGVHD) lead to significant morbidity, including functional disability from joint range of motion (ROM) restriction. No superior second-line therapy has been established for steroid-refractory disease. Imatinib mesylate is a multikinase inhibitor of several signaling pathways implicated in skin fibrosis with in vitro antifibrotic activity. We performed an open-label pilot phase II trial of imatinib in children and adults with corticosteroid-refractory ScGVHD. Twenty patients were enrolled in a 6-month trial. Eight received a standard dose (adult, 400 mg daily; children, 260 mg/m(2) daily). Because of poor tolerability, 12 additional patients underwent a dose escalation regimen (adult, 100 mg daily initial dose up to 200 mg daily maximum; children, initial dose 65 mg/m(2) daily up to 130 mg/m(2) daily). Fourteen patients were assessable for primary response, improvement in joint ROM deficit, at 6 months. Primary outcome criteria for partial response was met in 5 of 14 (36%), stable disease in 7 of 14 (50%), and progressive disease in 2 of 14 (14%) patients. Eleven patients (79%), including 5 with partial response and 6 with stable disease, demonstrated a positiv...Continue Reading

Associated Clinical Trials

References

Mar 1, 1984·The Journal of Hand Surgery·V MathiowetzN Kashman
Dec 22, 1999·Journal of the American Academy of Dermatology·M Grundmann-KollmannM Kerscher
Sep 18, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stephanie k LeeJoseph H Antin
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul OkunieffLynn H Gerber
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Mar 1, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Steven Z PavleticUNKNOWN Response Criteria Working Group
Jun 23, 2006·The New England Journal of Medicine·Silvia Svegliati BaroniArmando Gabrielli
Jun 2, 2007·Radiation Oncology·Nicole L SimoneKevin A Camphausen
Aug 19, 2009·Archives of Dermatology·Jason ClarkEdward W Cowen
Dec 4, 2009·The Journal of Hand Surgery·Erika Davis Sears, Kevin C Chung
Mar 20, 2010·Archives of Physical Medicine and Rehabilitation·Christine C Chen, Rita K Bode
Jun 15, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Philipp Yorck HerzbergDaniel Wolff
Nov 19, 2010·Current Rheumatology Reports·Jessica Gordon, Robert Spiera
Jul 30, 2011·Journal of Hand Therapy : Official Journal of the American Society of Hand Therapists·Ying-Chih WangWilliam Z Rymer
Jan 5, 2012·The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association·Brenda K Merritt
Jan 24, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kristin BairdSteven Z Pavletic
Feb 18, 2014·Blood·Jessica L AllenStefanie Sarantopoulos
Apr 24, 2014·Arthritis & Rheumatology·Yoshihiro InamotoUNKNOWN Chronic GVHD Consortium
May 2, 2014·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Hildegard T GreinixRobert Knobler

❮ Previous
Next ❯

Citations

Dec 3, 2015·Actas dermo-sifiliográficas·R Ballester-SánchezR Botella-Estrada
Sep 24, 2016·International Journal of Dermatology·Sima KavandRokea A El-Azhary
Jul 10, 2018·Oral Diseases·Hani MawardiNathaniel Treister
May 21, 2019·Expert Opinion on Drug Delivery·Behzad JafariYadollah Omidi
Dec 8, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Emily A RosenthalLeora E Comis
Jun 29, 2017·American Journal of Clinical Dermatology·Karla Strong RodriguesRobert Knobler
Jun 11, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Ayman SaadLenora Pluchino
Sep 18, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sally AraiMary E D Flowers
Nov 10, 2020·Frontiers in Immunology·Nathaniel Edward Bennett SaiduSara Galimberti
Dec 15, 2020·Current Dermatology Reports·Toral VaidyaAlina Markova
Dec 22, 2020·Therapeutic Advances in Hematology·Vladica M VelickovicTim Spelman
Feb 18, 2021·Clinical Transplantation·Ingrid Parra SalinasUNKNOWN Spanish Group of Hematopoietic Transplantation (GETH)
Oct 3, 2021·British Journal of Haematology·Noa G Holtzman, Steven Z Pavletic
Aug 12, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Lauren M CurtisSteven Z Pavletic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B cell Activation

B cell activation is initiated by the ligation of the B cell receptor with antigen and ultimately results in the production of protective antibodies against potentially pathogenic invaders. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.